Form 4: Supernus CEO Executes Planned Stock Option Exercise and Sale

Supernus Pharmaceuticals President and CEO Jack A. Khattar exercised employee stock options and subsequently sold a portion of the acquired common stock under a pre-established 10b5-1 trading plan.

Summary

• Jack A. Khattar, President, CEO, and Director of Supernus Pharmaceuticals, Inc. (SUPN), engaged in a series of transactions on September 23, 2025.
• Mr. Khattar exercised 47,940 employee stock options at an exercise price of $12.98 per share.
• Following the option exercise, Mr. Khattar sold 29,513 shares of common stock at a weighted average price of $47.23 per share, with individual sales ranging from $47.00 to $47.55.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on November 14, 2024.
• After these reported transactions, Mr. Khattar directly beneficially owns 1,140,883 shares of common stock.
• Additionally, Mr. Khattar indirectly beneficially owns 1,005,600 shares of common stock through the KBT Trust.

Sentiment

Score: 5

Explanation: The transaction represents a routine, pre-planned monetization of vested stock options by an executive, which is a common occurrence. While it involves insider selling, the existence of a 10b5-1 plan mitigates any negative sentiment regarding opportunistic trading, making the overall sentiment neutral.

Positives

• The executive is monetizing vested stock options, which is a common and legitimate financial activity for company leaders.
• The transactions were executed under a Rule 10b5-1 trading plan, indicating they were pre-scheduled and not based on immediate, non-public information, which enhances transparency and reduces concerns about opportunistic trading.

Negatives

• The sale of common stock by a high-ranking insider, even if planned, can sometimes be perceived negatively by some investors as a potential signal of reduced confidence in the company's near-term stock performance.

Future Outlook

NA

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are a common practice among executives in publicly traded companies across all industries, including pharmaceuticals. These plans allow insiders to sell shares at predetermined times or prices to avoid accusations of trading on material non-public information, providing a structured approach to managing personal portfolios.

Stakeholder Impact

• Shareholders may view the insider selling, even if planned, with mixed sentiment, potentially leading to minor short-term price fluctuations. However, the pre-planned nature under a 10b5-1 plan generally reduces concerns about opportunistic trading, suggesting a limited long-term impact on shareholder confidence.
• The transaction has no direct impact on employees, customers, suppliers, or creditors.

Key Dates

Recommendation

This Form 4 details a routine, pre-planned insider transaction (option exercise and sale) by the CEO under a 10b5-1 plan. Such transactions are common and do not typically signal a fundamental change in the company's outlook or warrant a shift in investment strategy based solely on this filing. Investors should consider the company's broader financial performance and strategic initiatives rather than reacting to this single, anticipated event.

Keywords

Supernus Pharmaceuticals, SUPN, Jack A. Khattar, Form 4, insider trading, stock option, 10b5-1 plan, beneficial ownership, executive compensation